Enzymatica AB

As of June 30, 2026, Enzymatica AB carries a market capitalization of 582.56M, placing it among publicly traded companies globally. Its enterprise value stands at 583.59M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Enzymatica AB's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Enzymatica AB has 242.74M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 12.89, and the price-to-book ratio stands at 5.93.

These figures are as of June 30, 2026. The EV/Sales ratio of 12.91 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 583.59M versus a market cap of 582.56M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Enzymatica AB maintains a current ratio of 8.01, meaning it holds 8.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.42, indicating elevated leverage, while an interest coverage ratio of -41.62 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Enzymatica AB posted a negative return on equity (ROE) of -40.52, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -33.97, reflecting losses generated across the asset base. The company generates approximately 2.23M in revenue per employee across its workforce of 20.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.22 indicates how many times Enzymatica AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Enzymatica AB recorded 542,000.00 in income tax expense. The company reported a pretax loss of -51.36M and -51.91M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Enzymatica AB's stock has declined approximately 2.02% over the past 52 weeks. The 50-day moving average sits at 1.85, while the 200-day moving average is 2.19.

Over the twelve months ended June 30, 2026, Enzymatica AB generated 45.20M in revenue and converted that into -51.91M in net income, yielding earnings per share of -0.21. EBITDA reached -51.35M, while operating income came in at -51.35M.

As of June 30, 2026, Enzymatica AB holds 13.15M in cash and equivalents against 14.17M in total debt, resulting in a net debt position of -13.14M. Total book value stands at 98.22M, with working capital of 31.89M providing operational flexibility.

Enzymatica AB produced -39.31M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Enzymatica AB posted a gross margin of 55.52, reflecting its pricing power and cost economics. The operating margin of -113.61 and net profit margin of -114.83 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -6.75: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.36, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Enzymatica AB shareholders.

Enzymatica AB's most recent stock split took place on August 23, 2024 with a 835:903 split ratio.